Mobile

A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000685-36

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to compare the PFS in subjects receiving cetuximab plus either UFOX or FOLFOX-4 as initial treatment for metastatic colorectal cancer.

Critère d'inclusion

  • Metastatic colorectal cancer

Liens